Nordic Nanovector ASA (NRNVF) Stock Price, News & Analysis

Company Overview

Nordic Nanovector ASA is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway, focused on the development of novel targeted therapies for the treatment of hematological cancers. The company’s core research effort centers on exploiting the potential of antibody-radionuclide conjugates to deliver cytotoxic payloads directly to malignant B cells, thereby maximizing tumor cell kill while sparing healthy tissue. Nordic Nanovector’s scientific platform integrates expertise in antibody engineering, radiochemistry and dosimetry to advance next-generation immuno-oncology therapies.

The company’s lead candidate, Betalutin (lilotomab satetraxetan), is a first-in-class, CD37-targeting therapeutic designed for patients with relapsed or refractory indolent non-Hodgkin lymphoma. Betalutin couples a humanized anti-CD37 antibody with the beta-emitting radionuclide lutetium-177, aiming to deliver localized radiation to malignant lymphocytes. Clinical studies conducted across multiple centers in Europe and North America have assessed safety, tolerability and preliminary efficacy, positioning Betalutin as a potential new treatment option for this underserved patient population.

In addition to its lead radiotherapeutic program, Nordic Nanovector is advancing a pipeline of complementary immuno-oncology assets and exploring strategic collaborations to broaden its therapeutic footprint. The management team brings together seasoned professionals in oncology drug development, regulatory affairs and commercial strategy, supported by a board of directors with deep experience in life sciences innovation. This combined expertise underpins the company’s translational approach, aiming to bridge early-stage research and late-stage development.

Nordic Nanovector serves a global community of patients and healthcare providers, maintaining operations in Norway, the United Kingdom and the United States. The company fosters partnerships with leading academic institutions and contract research organizations to drive its clinical trial programs. By leveraging a nimble organizational structure and a focused scientific strategy, Nordic Nanovector seeks to deliver transformative therapies that address critical needs in the treatment of blood cancers.

Key Stats

• Today's Range: $1.64 to $1.64
• 50-Day Range: $1.64 to $1.64
• 52-Week Range: $1.64 to $1.64
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRNVF Stock Analysis - Frequently Asked Questions

How have NRNVF shares performed this year?

Nordic Nanovector ASA's stock was trading at $1.6383 at the beginning of 2025. Since then, NRNVF stock has increased by 0.0% and is now trading at $1.6383.

How do I buy shares of Nordic Nanovector ASA?

Shares of NRNVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NRNVF
• CIK: N/A
• Web: www.nordicnanovector.com
• Phone: 47 22 18 33 01
• Fax: N/A
• Employees: 39
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A